NCT00890591View on ClinicalTrials.gov

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

PHASE4CompletedINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

August 31, 2007

Conditions

Essential Hypertension

Interventions

DRUG

olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks